Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inclusion body myositis

L H Calabrese1, S M Chou

  • 1Cleveland Clinic Foundation, Ohio.

Rheumatic Diseases Clinics of North America
|November 1, 1994
PubMed
Summary
This summary is machine-generated.

Idiopathic inflammatory myopathy (IBM) is not well understood, but recent advances offer hope. Further research is needed to determine if immunosuppressive therapy can slow disease progression and improve patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Intersection of COVID-19 and Autoimmunity: What is Our Current Understanding?

Pathogens & immunity·2021
Same author

Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma.

Clinical and experimental dermatology·2018
Same author

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2018
Same author

Externalised locking compression plate as an alternative to the unilateral external fixator: a biomechanical comparative study of axial and torsional stiffness.

Bone & joint research·2017
Same author

Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity.

RMD open·2017
Same author

Menstrual Abnormalities, Nutritional Patterns, and Body Composition in Female Classical Ballet Dancers.

The Physician and sportsmedicine·2016
Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
See all related articles

Area of Science:

  • Neurology
  • Immunology
  • Rheumatology

Background:

  • Idiopathic inflammatory myopathy (IBM) is a rare and poorly understood neuromuscular disease.
  • Recent advancements have improved clinical recognition and understanding of IBM's pathophysiology.

Purpose of the Study:

  • To evaluate the current understanding of IBM and identify key areas for future research.
  • To address the unanswered question of whether therapeutic interventions can positively impact short- and long-term outcomes in IBM patients.

Main Methods:

  • Review of recent literature on IBM clinical recognition and pathophysiology.
  • Analysis of emerging evidence regarding immunosuppressive therapy for IBM.

Main Results:

  • While progress has been made, IBM remains poorly understood.

Related Experiment Videos

  • Emerging reports suggest immunosuppressive therapy may slow disease progression.

    • Conclusions:

    • Long-term therapeutic trials are urgently needed to establish the efficacy of treatments for IBM.
    • Future trials should prioritize stabilization of strength as a primary outcome measure.